All In Biotech

Drug Trial Radar · NCT06006585

A Study to Test How Well Different Doses of BI 771716 Are Tolerated by People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy

Safety, Tolerability, and Pharmacokinetics of Intravitreal Single Rising Doses and Multiple Doses of BI 771716 in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration (Open Label, Non-randomized)

Last checked: Nov 20, 2026Latest source record: Feb 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

20

Actual

Start

Oct 6, 2023

Primary completion

May 24, 2024

Study completion May 24, 2024

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Aug 23, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to adults with geographic atrophy, an advanced form of age-related macular degeneration. People can join the study if they are at least 50 years old. The purpose of this study is to find out how well different doses of a medicine called BI 771716 are tolerated. This study has 2 parts. Part 1 of the study takes about 3 months. In this part, participants receive 1 injection of BI 771716 directly into one of the eyes affected by geographic atrophy. Part 2 of the study takes about 4 months. In this part, participants receive 2 injections of BI 771716 directly into the eye. There are 4 weeks between the first and the second injection. In this study, BI 771716 is given to humans for the first time. The doctors compare how well participants tolerate the different doses of BI 771716. The doctors also regularly check the general health of the participants.

Conditions

  • Geographic Atrophy

Interventions

  • BI 771716Drug

    BI 771716

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of ocular dose limiting events (DLEs) from drug administration until Day 8Time frame: Up to 7 days
  2. Occurrence of drug-related adverse events (AEs) from drug administration until end of study (EOS)Time frame: Up to 112 days

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Bay Area Retina Associates - Walnut Creek

    Walnut Creek, California

  • Florida Retina Institute

    Jacksonville, Florida

  • Florida Eye Associates

    Melbourne, Florida

  • Verum Research, LLC

    Eugene, Oregon

  • Erie Retina Research, LLC

    Erie, Pennsylvania

  • Tennessee Retina

    Nashville, Tennessee

  • Austin Clinical Research, LLC

    Austin, Texas

  • Retina Consultants of Houston, PA-Houston-62050

    Houston, Texas

  • Retina Consultants of Texas-The Woodlands-67575

    The Woodlands, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.